InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Court cases highlight product liability for licensors


A common objective of a brand owner when entering into a licensing agreement is to ensure that its licensee assumes all responsibility for manufacturing the licensed products and all liability for consequences as a result thereof. While the typical trade mark licence includes certain indemnification provisions aimed at ensuring that the licensor achieves this objective, a few recent court decisions have highlighted instances where such standard indemnification provisions do not sufficiently protect licensors. Such decisions reveal an emerging issue with respect to product liability that brand owners engaged in licensing their trade marks must pay careful attention to, namely the possibility that they will be held liable for injuries resulting from the...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Graphics showing what patent protection will cost in Europe, post- #unitarypatent ($/trial) http://t.co/EClJx919gW http://t.co/GBc0XfX2yz

Jul 3 2015 02:28 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @The_IPO: Do you work in #mediarelations or know someone who does? @The_IPO have a vacancy in our #London office http://t.co/SkHPfN2yIY

Jul 3 2015 01:48 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @OAMITWEETS: Our webinar programme for July 7 http://t.co/CbPXRi0ITB

Jul 3 2015 11:45 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements